BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 21, 2013
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 1/18 cls
AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) Leerink Joseph Schwartz Upgrade Outperform (from market perform) -3% $15.47
Schwartz also raised his target to $19 from $17, saying he believes sales expectations for Feraheme ferumoxytol are now achievable. He noted that AMAG management has "shifted the company's strategy away from heavy product discounting and rebating and positioned Feraheme well ahead of the broader iron deficiency anemia (IDA) opportunity." In December, AMAG submitted an sNDA to FDA to expand the indication to include the treatment of all adults with IDA who have failed or could not tolerate oral iron treatment (see BioCentury, Jan. 7). The IV iron replacement therapy already is approved to treat IDA in adults with chronic kidney disease (CKD). Schwartz estimates U.S. Feraheme sales of $66.4M in 2013 and $90.6M in 2014.

Read the full 862 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >